Eurotimes Articles

  • 01/24/2014 - 15:09 MAHALO TRIAL Feb, 2014, Retina Monthly injections of the biologic agent lampalizumab (Roche) can significantly reduce the rate of progression of geographic atrophy (GA), according to the results of the MAHALO phase II trial, which Frank Holz MD presented at the 13th EURETINA Congress in Hamburg.
  • 01/24/2014 - 14:40 GEOGRAPHIC ATROPHY Feb, 2014, Retina Will geographic atrophy (GA) be treatable by 2020? Based on current rates of progress and the growing momentum behind clinical trials related to the disease, the answer is a guarded “yes”, according to Monika Fleckenstein MD.
  • 01/24/2014 - 13:37 EPISCLERAL DEVICES Feb, 2014, Retina A minimally invasive retrobulbar episcleral brachytherapy device (SalutarisMD™, Salutaris Medical Devices) has shown promise in the treatment of a small cohort of exudative AMD patients, according to Kamaljit Balaggan MRCOphth, PhD. Dr Balaggan, Moorfields Eye Hospital, London and Department of Genetics at the University College London Institute of Ophthalmology, reported the feasibility and tolerability of the SalutarisMD investigational treatment for wet AMD using a single dose of episcleral brachytherapy in conjunction with intraocular anti-VEGF injections.
  • 01/24/2014 - 13:34 DME DEVELOPMENTS Feb, 2014, Retina Advanced imaging techniques allied to potent new anti-VEGF and steroid therapies have radically transformed the prognosis and management of patients with diabetic macular oedema and other debilitating retinal diseases over the past decade, according to Francesco Bandello MD, FEBO. “We are living in exciting times for retinal experts. We have new diagnostic tools and new therapeutic options where we are able to modify the management of many retinal diseases.
  • 01/24/2014 - 13:23 AMD GENOTYPING Feb, 2014, Retina Genetic risk assessment for agerelated macular degeneration (AMD) should be part of the patient selection process for multifocal IOLs, Steve A Arshinoff MD told delegates at the XXXI Congress of the ESCRS in Amsterdam.
  • 01/24/2014 - 12:55 ADAPTIVE OPTICS Feb, 2014, Retina Adaptive optics scanning laser ophthalmoscopy (AOSLO) allows non-invasive, in vivo visualisation of the retinal microstructures of a living human eye and may help to pave the way to earlier detection and better management of a range of retinal pathologies, according to Wolf M Harmening PhD.
  • 12/10/2013 - 13:48 OCULAR TUMOURS 2013, Retina, Dec Radiotherapy has made major advances in recent years in offering a viable treatment modality to patients with ocular tumours that were once deemed inoperable, according to Leonidas Zografos.
  • 12/10/2013 - 13:40 IMAGING AMD 2013, Retina, Dec OCT can be a highly useful tool for predicting visual outcomes in patients with neovascular AMD, according to Sebastian M Waldstein MD, Medical University of Vienna, Vienna, Austria. “OCT is the most valuable tool in our hands. We know that it gives the highest resolution, is able to quantify changes in terms of progression and it certainly has the strongest predictive value,” Dr Waldstein told the 13th EURETINA Congress.
  • 11/05/2013 - 11:56 DRUGS COMPARABLE 2013, Retina, Nov A multicentre French study comparing bevacizumab (Avastin, Genentech) and ranibizumab (Lucentis, Genentech) found that both drugs were comparable in terms of clinical efficacy for the treatment of neovascular age-related macular degeneration (AMD)
  • 10/06/2013 - 09:02 MACULAR DISEASE 2013, Retina, Oct Age-related macular degeneration (AMD) constitutes one of the main causes of macular disease in an elderly population, affecting about one in every seven patients examined in a recent French population study, according to Catherine Creuzot- Garcher MD, PhD, FEBO.

Popular Items